Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2] Group 1: Class Action Details - The class action lawsuit has been filed against RxSight, Inc. for allegedly misleading statements regarding the company's growth and performance during the Class Period [4] - Investors who purchased RxSight securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - The lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members in the litigation [2] Group 2: Allegations Against RxSight - The lawsuit claims that RxSight misrepresented the effectiveness of its field organization and the adoption rates of newer customer cohorts, which were actually underperforming [4] - It is alleged that the utilization across the installed base was declining, contradicting the company's claims of rising utilization [4] - As a result of these misleading statements, investors purchased shares at artificially inflated prices, leading to financial damages when the truth was revealed [4] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3] - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [3]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, alleging misleading statements regarding the company's drug application process [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Savara made false statements about the MOLBREEVI Biologics License Application (BLA), indicating it lacked sufficient information for FDA approval [5]. - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which could delay Savara's submission timeline and increase the need for additional capital [5]. - The lawsuit asserts that these misleading statements caused investors to suffer damages when the true information became public [5]. Group 2: Class Action Participation - Investors who purchased Savara securities during the class period may be entitled to compensation without upfront fees through a contingency fee arrangement [2]. - To join the class action, investors can submit a form online or contact the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by November 7, 2025, to represent the interests of the class members [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of KBR, Inc. securities purchasers during the specified Class Period, alleging that the company made materially false and misleading statements regarding its business operations and prospects [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to KBR, Inc. securities purchased between May 6, 2025, and June 19, 2025 [1]. - The lawsuit claims that KBR's management misrepresented the status of its partnership with the U.S. Department of Defense's Transportation Command, despite known concerns about HomeSafe's ability to fulfill contractual obligations [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by November 18, 2025, to represent the class in the litigation [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - RCI Hospitality Holdings, Inc. is under investigation for potentially issuing misleading business information, following allegations of bribery involving its executives and a New York state auditor, which has led to a significant drop in its stock price [1][3]. Group 1: Investigation and Allegations - The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of RCI Hospitality Holdings due to allegations of materially misleading business information [1]. - Allegations include that top executives of RCI Hospitality Holdings bribed a New York state auditor with trips and lap dances to avoid paying taxes, as reported by The New York Times [3]. Group 2: Stock Impact - Following the news of the bribery allegations, RCI Hospitality Holdings' stock experienced a decline of 16% on September 16, 2025 [3]. Group 3: Legal Actions - The Rosen Law Firm is preparing a class action lawsuit to seek recovery of investor losses, allowing affected shareholders to join without upfront costs [2].

Core Viewpoint - A class action lawsuit has been filed against Fly-E Group, Inc. for allegedly making false and misleading statements regarding its lithium battery technology and its impact on the company's revenue from electric vehicles [1][3]. Summary by Relevant Sections Class Action Details - The lawsuit seeks to recover losses for investors who purchased Fly-E securities between July 15, 2025, and August 14, 2025 [1]. - Investors have until November 7, 2025, to seek appointment as lead plaintiff if they suffered losses during the Class Period [2]. Allegations Against Fly-E Group - The lawsuit claims that Fly-E Group and certain officers failed to disclose safety issues with their lithium battery technology while making positive public statements [3]. - Allegations include that these undisclosed safety and regulatory concerns negatively affected revenue from the company's electric vehicle business, including e-bikes and e-scooters [3]. - The complaint also asserts that the company's forecasts lacked a reasonable basis, failing to account for rising operating costs, supply chain risks, and demand fluctuations [3]. - Following the revelation of these issues, the company's stock price declined as investors reacted to the disclosures [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased CTO Realty Growth, Inc. securities between February 18, 2021, and June 24, 2025, of the upcoming lead plaintiff deadline on October 7, 2025 [1]. Group 1: Class Action Details - Investors who purchased CTO Realty securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 7, 2025 [3]. - The lawsuit alleges that CTO Realty Growth made false and misleading statements regarding the sustainability of its dividends and the profitability of its Ashford Lane property, leading to overstated business and financial prospects [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - A lawsuit has been filed against Lineage, Inc. and its senior executives for potential violations of federal securities laws related to its IPO and subsequent financial performance [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Eastern District of Michigan, specifically titled City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., et al., No. 2:25-cv-12383 [2]. - Investors who purchased stock during Lineage's IPO on or about July 25, 2024, are represented in the lawsuit, which asserts claims under Sections 11 and 15 of the Securities Act of 1933 [2][4]. Group 2: Company Overview - Lineage, Inc. operates as a cold storage-focused real estate investment trust (REIT), owning and managing temperature-controlled storage facilities for perishable products [3]. - The company claimed in its IPO documents that it had "consistent cold chain demand" and strong cash flows, even during economic downturns [4]. Group 3: Financial Performance and Market Reaction - Following the IPO, Lineage's stock price has significantly declined from an initial price of $78 per share to around $40 per share, approximately half of its IPO value [5]. - In its fiscal Q4 2024 results announced on February 26, 2025, Lineage indicated that customers were "unwinding" excess inventory, returning to a more normal seasonal pattern [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, of the October 6, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To join the class action, investors can submit a form online or contact the law firm directly for more information [2][5] - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, failing to meet a key statistical significance marker related to fibrosis reduction [4] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a press release from Tandem Diabetes Care on August 7, 2025, regarding a voluntary medical device correction for select t:slim X2 insulin pumps, which indicated a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 2: Class Action Information - Shareholders who purchased Tandem Diabetes Care securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and consistently ranking in the top 4 for securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Group 1 - A lawsuit has been filed against Charter Communications, Inc. and certain senior executives for potential violations of federal securities laws [1][2] - The lawsuit claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, with a deadline for investors to seek lead plaintiff status by October 14, 2025 [2] - Charter is a leading broadband and cable operator that participated in the FCC's Affordable Connectivity Program, which ended in June 2024 due to lack of federal funding, leading to customer declines [3] Group 2 - During the relevant period, Charter communicated to investors that it was managing the impact of the Affordable Connectivity Program's end, claiming the effects were behind them [4] - Contrary to these statements, Charter continued to experience declines in internet customers and revenue following the program's termination [4] - On July 25, 2025, Charter reported a decrease of 117,000 total internet customers in Q2 2025, with approximately 50,000 disconnects attributed to the end of the program, resulting in an 18.4% stock price decline [5]